Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
Key takeaways
- According to a May 15, 2026, SEC filing, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS) by purchasing 1,100,000 shares over the first quarter.
- This was a new position for Boxer Capital Management, representing 2.11% of March 31, 2026, reportable AUM.
- NASDAQ:TNGX: $227.53 million (29.9% of AUM)
Jonathan Ponciano, The Motley Fool Mon, May 18, 2026 at 3:46 AM GMT+7 4 min read CRVS TNGX CELC KOD RVMD On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing.
According to a May 15, 2026, SEC filing, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS) by purchasing 1,100,000 shares over the first quarter. The estimated transaction value is $17.55 million, calculated using the average closing price for the period. The fund reported a quarter-end position value of $16.09 million for Corvus Pharmaceuticals, reflecting both share accumulation and price shifts.
This was a new position for Boxer Capital Management, representing 2.11% of March 31, 2026, reportable AUM.